Valuation: Yunnan Botanee Bio-Technology Group Co.LTD

Capitalization 18.23B 2.64B 2.27B 2.06B 1.98B 3.61B 244B 3.74B 24.22B 9.7B 116B 9.92B 9.7B 415B P/E ratio 2025 *
33.4x
P/E ratio 2026 * 27.8x
Enterprise value 16.94B 2.45B 2.11B 1.92B 1.84B 3.35B 226B 3.48B 22.5B 9.01B 108B 9.21B 9.02B 385B EV / Sales 2025 *
2.99x
EV / Sales 2026 * 2.72x
Free-Float
32.1%
Yield 2025 *
1.32%
Yield 2026 * 1.52%
02-11 Yunnan Botanee Bio-Technology Group Co.Ltd Proposes Dividend for the Third Quarter of 2025 CI
01-12 Yunnan Botanee Bio-Technology Group's shareholder plans to cut stake RE
12-10 Suzhou Zisong Medical Technology Co., Ltd announced that it has received funding from Yunnan Botanee Bio-Technology Group Co.LTD, Beijing Zhongguancun Qihang Venture Capital and other investors CI
27/10/25 Yunnan Botanee Bio-Technology Group Co.LTD Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
29/08/25 Macquarie Downgrades Yunnan Botanee Bio-Technology Group to Underperform from Outperform; Price Target is 42 Yuan MT
27/08/25 Yunnan Botanee Bio-Technology Group Co.LTD Reports Earnings Results for the Half Year Ended June 30, 2025 CI
24/07/25 Yunnan Botanee Bio-Technology's shareholder to unload shares RE
30/06/25 Shanghai Ruishi Health Technology Co., Ltd. announced that it has received funding from Beijing Jinke Hightech Innovation Ventures Co., Ltd., Sinovation Ventures Enterprise Management Limited, Yaojin Private Equity Fund Management Co., Ltd., Yunnan Botanee Bio-Technology Group Co.LTD, BRV Partners, LLC and other investors CI
16/05/25 Yunnan Botanee Bio-Technology Group Co.LTD Approves Board Appointments CI
16/05/25 Yunnan Botanee Bio-Technology Group Co.Ltd Approves Cash Dividend for the Year 2024 on A Shares, Payable on 30 May 2025 CI
07/05/25 A group of buyers completed the acquisition of 2.50% stake in Yunnan Botanee Bio-Technology Group Co.LTD from Tianjin Sequoia Juye Equity Investment Partnership Enterprise (Limited Partnership), Kunming Zhenli Consulting Co., Ltd. and HongShan for CNY 350 million. CI
28/04/25 Jefferies Adjusts Yunnan Botanee Bio-Technology's Price Target to 42 Yuan From 62 Yuan, Keeps at Hold MT
25/04/25 Yunnan Botanee Bio-Technology Group Co.Ltd Proposes Dividend for the Year 2024 CI
1 day-1.13%
1 week-8.18%
Current month-7.57%
1 month-2.83%
3 months+8.63%
6 months-5.12%
Current year+9.97%
1 week 43.28
Extreme 43.28
47.14
1 month 43.28
Extreme 43.28
49.79
Current year 39.63
Extreme 39.63
49.79
1 year 37.46
Extreme 37.46
51.8
3 years 37.46
Extreme 37.46
138.5
5 years 37.46
Extreme 37.46
289.35
10 years 37.46
Extreme 37.46
289.35
Manager TitleAgeSince
Chief Executive Officer 63 01/12/2016
Director of Finance/CFO 44 01/12/2016
Corporate Officer/Principal 47 01/07/2012
Director TitleAgeSince
Director/Board Member 58 01/10/2013
Chairman 63 01/06/2014
Director/Board Member 62 01/03/2019
Change 5d. change 1-year change 3-years change Capi.($)
-1.13%-8.18%+1.75%-68.56% 2.65B
-0.57%-6.48%+2.00%-1.73% 232B
+6.73%+5.48%+37.12% - 44.05B
-1.94%-5.94%-4.50%+23.71% 18.28B
+1.13%-4.25%+6.78%-52.42% 7.65B
-9.52%-20.13%+8.38%-13.93% 5.32B
+0.43%-13.74%+25.61%+6.80% 4.74B
-0.06%-6.48%-20.28%-49.18% 3.83B
-0.66%-7.39%-29.12%-32.79% 3.02B
+0.36%-10.47%+54.23%+101.61% 2.86B
Average -0.56%-8.18%+8.20%-9.61% 32.48B
Weighted average by Cap. +0.17%-5.65%+6.87%-2.10%

Financials

2025 *2026 *
Net sales 5.67B 821M 706M 641M 615M 1.12B 75.72B 1.16B 7.53B 3.01B 36.11B 3.08B 3.02B 129B 6.22B 901M 775M 703M 674M 1.23B 83.05B 1.28B 8.26B 3.31B 39.61B 3.38B 3.31B 141B
Net income 550M 79.66M 68.5M 62.16M 59.62M 109M 7.34B 113M 730M 292M 3.5B 299M 293M 12.51B 661M 95.71M 82.3M 74.68M 71.63M 131M 8.82B 136M 877M 351M 4.21B 359M 352M 15.03B
Net Debt -1.29B -187M -161M -146M -140M -256M -17.26B -265M -1.72B -687M -8.23B -703M -688M -29.39B -1.31B -190M -163M -148M -142M -260M -17.52B -269M -1.74B -697M -8.35B -713M -698M -29.83B
Logo Yunnan Botanee Bio-Technology Group Co.LTD
Yunnan Botanee Bio-Technology Group Co LTD is a Chinese company mainly engaged in the production of cosmetics. The Company adopts a sales model based on offline channel sales and online channel sales as the leading factor. The Company's products mainly include creams, skin care lotions, facial masks, essences, lotions and other skin care products and make-up products such as isolation creams, blemish balm (BB) creams, and makeup removers. The Company is also engaged in the research and development, production and sales of skin care-related medical device products, mainly including hyaluronic acid repairing biofilm, hyaluronic acid repairing dressings, mainly used for the protection of skin with damaged barriers after minimally invasive surgery and care.
Employees
3,956
Date Price Change Volume
05/03/26 43.42 ¥ -0.32% 4,015,921
04/03/26 43.56 ¥ -1.13% 4,889,377
03/03/26 44.06 ¥ -3.59% 5,910,920
02/03/26 45.70 ¥ -3.03% 5,404,055
27/02/26 47.13 ¥ +0.88% 3,396,254
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
43.56CNY
Average target price
45.42CNY
Spread / Average Target
+4.26%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300957 Stock